CClinicalTrials.gg
Sign In
Status unknownNCT03546010TDAHUpdated Jun 6, 2018

Oculometry as an Attentional Mechanism Evaluation Tool and Attention Deficit Hyperactivity Inhibition

An interventional study of Neuropsychological tests and Oculometric tests in Attention Deficit-Hyperactivity, sponsored by University Hospital, Grenoble. Status unknown at 1 site in France. Open to participants aged 8 Years to 12 Years. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Jun 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled May 2014, registered May 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
8 Years to 12 Years
Sex
All
01

Study summary

The aim of this study is to analyse thanks to eye tracking experiments ocular movement classical parameters in children with attention deficit hyperactivity (ADH) and to compare them to results obtained in healthy children and to results obtained with neuropsychological tests commonly used in standard health care.

We should then be able to compare eye tracking with neuropsychological parameters.

The final objective is to give to health professional a tool for ADH investigation with which they should be able to do a simple and effective follow up of children with ADH.

02

Conditions studied

  • Attention Deficit-Hyperactivity
03

In context

Hyperkinesis

729 studies on the registry are indexed under Hyperkinesis; 25 are open to participants now.

This study's planned enrollment of 60 is below the median of 80 across 583 interventional studies indexed under Hyperkinesis.

Browse Hyperkinesis studies →

Lead sponsor

University Hospital, Grenoble is the lead sponsor of 815 studies on the registry; 205 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children between 8 and 12 years old
  • Boys and girls
  • DSM-IV-TR diagnostic criteria for ADH
  • Children with methylprednisone treatment
  • Social security affiliation
  • signed informed consent

Exclusion criteria

Exclusion Criteria:

  • specialised scholarship
  • refusal from children or parents
  • too law results in WISC test (pre-inclusion test)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Oculometric and neuropsychological tests

    Oculometric tests and neuropsychological tests

    Behavioral: Neuropsychological tests · Behavioral: Oculometric tests

Interventions

  • BehavioralNeuropsychological tests

    WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test

  • BehavioralOculometric tests

    When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.

06

What researchers measure

Primary outcomes

  1. Correlation between oculometric and neuropsychological tests in ADH evaluation

    Differentiation between simple oculomotor disorder and attentional-visual disorder

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • Grenoble Alps Hospital
    Grenoble, France
    • Annie Laurent, MD · Contact
    Recruiting
08

References and documents

Publications

  • Malsert J, Guyader N, Chauvin A, Polosan M, Szekely D, Bougerol T, Marendaz C. Saccadic performance and cortical excitability as trait-markers and state-markers in rapid cycling bipolar disorder: a two-case follow-up study. Front Psychiatry. 2013 Jan 4;3:112. doi: 10.3389/fpsyt.2012.00112. eCollection 2012. PubMed 23293609 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03546010
Lead sponsor
University Hospital, Grenoble
Responsible party
Sponsor
First posted
Jun 6, 2018
Start date
May 5, 2014
Primary completion
Dec 31, 2018 (estimated)
Completion
Dec 31, 2018 (estimated)
Last update
Jun 6, 2018

Study contacts

Annie Laurent, MD
Contact
AnnieLaurent@chu-grenoble.fr
04 76 76 54 19
Nathalie Guyader, MCD UJF
Contact
nathalie.guyader@gipsa-lab.grenoble-inp.fr
04 76 57 43 72
Annie Laurent, MD
principal investigator · Grenoble Alps University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hyperkinesis→

Other studies from this sponsor

University Hospital, Grenoble

Start the discussion